undamentalytics Newsletter

Hedge fund

Baker Bros. Advisors LP

13F for the quarter to June 30, 2026, filed August 14, 2026 · SEC CIK 1263508

Reported value
$19.9bn
100% in companies we cover
Positions we cover
80
Largest INCY 17.5%
Copy, a year
+11.0%
S&P 500 +14.1%
Copy Sharpe ratio
0.42
S&P 500 0.78

How copying its 13F would have done

$10.0k$20.0k$40.0k 2013201520172019202120232025 $57.0k$39.8k
CopyS&P 500 $10,000 copying Baker Bros. Advisors LP's filed holdings in companies we cover from August 16, 2013, buying on the first trading day after each 13F was filed and holding until the next, against the S&P 500 (total return). Marked weekly, log scale. Before costs and taxes; misses trading within each quarter and anything 13F does not show (shorts, cash, bonds, non-US holdings).

Biggest drop −60.3% (S&P 500 −31.8%); beta 0.97; alpha +2.0% a year (t = 0.24); last 12 months +27.9% against +12.1%.

Reported value by quarter

Baker Bros. Advisors LP: 13F reported value Total value of all positions in each quarter's 13F, as filed (values before 2023 were filed in thousands of dollars and are converted).
$0 $5T $10T $15T $20T Reported value, 2013-06-30: $4B Reported value, 2013-09-30: $5.6B Reported value, 2013-12-31: $5.4B Reported value, 2014-03-31: $5.9B Reported value, 2014-06-30: $6.2B Reported value, 2014-09-30: $5.9B Reported value, 2014-12-31: $7.7B Reported value, 2015-03-31: $9.4B Reported value, 2015-06-30: $9.4B Reported value, 2015-09-30: $9.1B Reported value, 2015-12-31: $10.3B Reported value, 2016-03-31: $8.1B Reported value, 2016-06-30: $8.3B Reported value, 2016-09-30: $9.7B Reported value, 2016-12-31: $9B Reported value, 2017-03-31: $12B Reported value, 2017-06-30: $11.3B Reported value, 2017-09-30: $12.2B Reported value, 2017-12-31: $11.4B Reported value, 2018-03-31: $11.7B Reported value, 2018-06-30: $13.2B Reported value, 2018-09-30: $15.2B Reported value, 2018-12-31: $12.1B Reported value, 2019-03-31: $15.5B Reported value, 2019-06-30: $14.7B Reported value, 2019-09-30: $14.6B Reported value, 2019-12-31: $18.7B Reported value, 2020-03-31: $16.2B Reported value, 2020-06-30: $22.6B Reported value, 2020-09-30: $25B Reported value, 2020-12-31: $26.5B Reported value, 2021-03-31: $23B Reported value, 2021-06-30: $22.6B Reported value, 2021-09-30: $22.6B Reported value, 2021-12-31: $20.4B Reported value, 2022-03-31: $17.3B Reported value, 2022-06-30: $17.5B Reported value, 2022-09-30: $15.2B Reported value, 2022-12-31: $16.6T Reported value, 2023-03-31: $18.4B Reported value, 2023-06-30: $17.1B Reported value, 2023-09-30: $17.2B Reported value, 2023-12-31: $8.7B Reported value, 2024-03-31: $8B Reported value, 2024-06-30: $7.7B Reported value, 2024-09-30: $9.6B Reported value, 2024-12-31: $9.2B Reported value, 2025-03-31: $8.9B Reported value, 2025-06-30: $10.3B Reported value, 2025-09-30: $13.8B Reported value, 2025-12-31: $17B Reported value, 2026-03-31: $17.4B Reported value, 2026-06-30: $19.9B 2013-06-30 2016-03-31 2018-12-31 2021-09-30 2026-06-30 $19.9B
View chart data
Period Reported value
2013-06-30 $4B
2013-09-30 $5.6B
2013-12-31 $5.4B
2014-03-31 $5.9B
2014-06-30 $6.2B
2014-09-30 $5.9B
2014-12-31 $7.7B
2015-03-31 $9.4B
2015-06-30 $9.4B
2015-09-30 $9.1B
2015-12-31 $10.3B
2016-03-31 $8.1B
2016-06-30 $8.3B
2016-09-30 $9.7B
2016-12-31 $9B
2017-03-31 $12B
2017-06-30 $11.3B
2017-09-30 $12.2B
2017-12-31 $11.4B
2018-03-31 $11.7B
2018-06-30 $13.2B
2018-09-30 $15.2B
2018-12-31 $12.1B
2019-03-31 $15.5B
2019-06-30 $14.7B
2019-09-30 $14.6B
2019-12-31 $18.7B
2020-03-31 $16.2B
2020-06-30 $22.6B
2020-09-30 $25B
2020-12-31 $26.5B
2021-03-31 $23B
2021-06-30 $22.6B
2021-09-30 $22.6B
2021-12-31 $20.4B
2022-03-31 $17.3B
2022-06-30 $17.5B
2022-09-30 $15.2B
2022-12-31 $16.6T
2023-03-31 $18.4B
2023-06-30 $17.1B
2023-09-30 $17.2B
2023-12-31 $8.7B
2024-03-31 $8B
2024-06-30 $7.7B
2024-09-30 $9.6B
2024-12-31 $9.2B
2025-03-31 $8.9B
2025-06-30 $10.3B
2025-09-30 $13.8B
2025-12-31 $17B
2026-03-31 $17.4B
2026-06-30 $19.9B

Holdings and moves

CompanyShare of portfolioValueSharesChange in shares
INCYIncyte17.54%$3.5bn30.76M+0.1%
ONCBeone Medicines Ltd.12.61%$2.5bn8.80M0.0%
RVMDRevolution Medicines, Inc.10.78%$2.1bn11.44M+19.8% Added
MDGLMadrigal Pharmaceuticals, Inc.5.79%$1.2bn2.14M+0.1%
ACADAcadia Pharmaceuticals Inc5.46%$1.1bn42.91M0.0%
KYMRKymera Therapeutics, Inc.4.99%$992.7m8.66M0.0%
INSMInsmed Inc4.72%$937.8m8.80M+18.5% Added
CELCCelcuity Inc.4.16%$828.2m7.92M0.0%
KODKodiak Sciences Inc.3.90%$776.1m19.92M0.0%
RYTMRhythm Pharmaceuticals, Inc.3.13%$622.3m5.60M0.0%
PRAXPraxis Precision Medicines, Inc.2.95%$587.0m1.75M0.0%
ALKSAlkermes plc.2.64%$524.6m10.01M0.0%
SMMTSummit Therapeutics Inc.2.40%$477.7m32.79M−9.9% Reduced
GRALGrail, Inc.1.38%$275.0m4.03M0.0%
ABCLAbcellera Biologics Inc.1.30%$259.1m33.01M+9.0% Added
IMVTImmunovant, Inc.1.05%$209.4m5.44M−0.4%
IDYAIdeaya Biosciences, Inc.0.94%$186.7m5.01M+26.9% Added
KNSAKiniksa Pharmaceuticals International, plc0.91%$181.3m2.83M+0.3%
ROIVRoivant Sciences Ltd.0.84%$166.9m4.72M−3.1% Reduced
ARWRArrowhead Pharmaceuticals, Inc.0.82%$162.4m1.99M0.0%
IONSIonis Pharmaceuticals Inc0.82%$162.4m2.05M0.0%
EWTXEdgewise Therapeutics, Inc.0.76%$150.4m3.70M−43.7% Reduced
REPLReplimune Group, Inc.0.61%$122.3m11.05M0.0%
NRIXNurix Therapeutics, Inc.0.57%$113.0m4.66M0.0%
STOKStoke Therapeutics, Inc.0.55%$109.2m3.34M0.0%
GLUEMonte Rosa Therapeutics, Inc.0.53%$105.2m4.35M0.0%
IMTXImmatics N.V.0.48%$96.3m9.51M−12.9% Reduced
DNLIDenali Therapeutics Inc.0.48%$96.0m3.73M+0.1%
DNTHDianthus Therapeutics, Inc.0.42%$83.1m852.2K0.0%
GPCRStructure Therapeutics Inc.0.39%$76.9m1.43M0.0%
RAPPRapport Therapeutics, Inc.0.32%$64.5m1.55M0.0%
ALMSAlumis Inc.0.28%$56.6m2.01M0.0%
PRLDPrelude Therapeutics Inc0.27%$54.0m10.12M0.0%
RLAYRelay Therapeutics, Inc.0.27%$52.9m2.83M+143.7% Added
MIRMMirum Pharmaceuticals, Inc.0.26%$52.2m446.0K0.0%
BCYCBicycle Therapeutics PLC0.23%$46.2m10.89M0.0%
ELVNEnliven Therapeutics, Inc.0.23%$45.9m905.2K0.0%
CLDXCelldex Therapeutics, Inc.0.22%$44.0m1.18M+77.7% Added
VRDNViridian Therapeutics, Inc.\de0.22%$43.8m2.38M+20.9% Added
DSGNDesign Therapeutics, Inc.0.20%$38.8m2.68M+3.6% Added
TRDAEntrada Therapeutics, Inc.0.19%$37.3m5.07M0.0%
FTHFaeth Therapeutics, Inc.0.16%$32.2m1.29MNew
AKTSAktis Oncology, Inc.0.16%$32.1m996.4K0.0%
NGNENeurogene Inc.0.16%$31.2m991.7K0.0%
JBIOJade Biosciences, Inc.0.14%$27.3m1.23M−25.0% Reduced
TSHATaysha Gene Therapies, Inc.0.14%$27.3m4.00M0.0%
RCUSArcus Biosciences, Inc.0.13%$26.0m844.8K+103.3% Added
IRONDisc Medicine, Inc.0.13%$25.6m349.7K0.0%
ABSIAbsci Corp0.12%$24.7m2.13M0.0%
GENBGenerate Biomedicines, Inc.0.12%$24.0m1.42M0.0%
DBVTDBV Technologies S.a.0.12%$24.0m1.46M0.0%
XENEXenon Pharmaceuticals Inc.0.11%$22.3m370.2K0.0%
TECXTectonic Therapeutic, Inc.0.10%$20.9m607.8K0.0%
CERSCerus Corp0.09%$18.7m6.40M−36.1% Reduced
CTMXCytomx Therapeutics, Inc.0.09%$18.7m4.98M0.0%
DYNDyne Therapeutics, Inc.0.09%$18.1m813.4K0.0%
CYTKCytokinetics Inc0.09%$18.0m211.3KNew
XNCRXencor Inc0.09%$17.7m1.10M0.0%
SIONSionna Therapeutics, Inc.0.09%$17.6m400.0K0.0%
NTLAIntellia Therapeutics, Inc.0.08%$15.7m930.2KNew
PBLSParabilis Medicines, Inc.0.07%$13.7m500.0KNew
MPLTMaplight Therapeutics, Inc.0.07%$13.1m364.7K0.0%
AVLNAvalyn Pharma Inc.0.06%$11.5m350.0KNew
EVMNEvommune, Inc.0.06%$11.3m847.4K0.0%
BNTXBiontech SE0.06%$11.1m119.7K0.0%
TNGXTango Therapeutics, Inc.0.05%$10.4m333.3KNew
AVTXAvalo Therapeutics, Inc.0.05%$10.2m550.0KNew
SERASera Prognostics, Inc.0.05%$10.0m5.50M0.0%
VSTMVerastem, Inc.0.05%$9.5m2.50M+327.4% Added
SGMTSagimet Biosciences Inc.0.04%$7.4m953.0K0.0%
EIKNEikon Therapeutics, Inc.0.04%$7.2m555.6K0.0%
LBRXLB Pharmaceuticals Inc0.03%$6.5m200.0K0.0%
VTVTVtv Therapeutics Inc.0.03%$5.6m148.3K0.0%
TARAProtara Therapeutics, Inc.0.02%$3.7m971.6K0.0%
TCRXTscan Therapeutics, Inc.0.01%$2.7m2.78M0.0%
IMNMImmunome Inc.0.01%$1.2m55.3KNew
SKYESkye Bioscience, Inc.0.01%$1.1m1.58M0.0%
SANASana Biotechnology, Inc.0.01%$1.1m310.5K0.0%
ALGSAligos Therapeutics, Inc.0.00%$479,22783.1K0.0%
TYRATyra Biosciences, Inc.0.00%$338,78810.6K0.0%
CompanyBought (value)Shares
RVMDRevolution Medicines, Inc.$353.6m1.89M
INSMInsmed Inc$146.6m1.38M
IDYAIdeaya Biosciences, Inc.$39.6m1.06M
FTHFaeth Therapeutics, Inc.$32.2m1.29M
RLAYRelay Therapeutics, Inc.$31.2m1.67M
ABCLAbcellera Biologics Inc.$21.5m2.74M
CLDXCelldex Therapeutics, Inc.$19.2m517.2K
CYTKCytokinetics Inc$18.0m211.3K
NTLAIntellia Therapeutics, Inc.$15.7m930.2K
PBLSParabilis Medicines, Inc.$13.7m500.0K
RCUSArcus Biosciences, Inc.$13.2m429.2K
AVLNAvalyn Pharma Inc.$11.5m350.0K
TNGXTango Therapeutics, Inc.$10.4m333.3K
AVTXAvalo Therapeutics, Inc.$10.2m550.0K
VRDNViridian Therapeutics, Inc.\de$7.6m411.3K

Change in shares on the previous quarter's 13F, valued at this quarter's reported price.

CompanySold (value)Shares
EWTXEdgewise Therapeutics, Inc.−$116.8m−2.87M
ABVXAbivax S.a.−$97.5m−875.8K
SMMTSummit Therapeutics Inc.−$52.5m−3.60M
SYRESpyre Therapeutics, Inc.−$50.4m−1.00M
IMCRImmunocore Holdings plc−$22.1m−734.4K
CTNMContineum Therapeutics, Inc.−$18.6m−1.42M
ARGXArgenx SE−$18.4m−25.2K
IMTXImmatics N.V.−$14.3m−1.41M
CMPSCompass Pathways plc−$13.0m−2.34M
PHVSPharvaris N.V.−$10.6m−375.0K
CERSCerus Corp−$10.5m−3.61M
JBIOJade Biosciences, Inc.−$9.1m−410.7K
ROIVRoivant Sciences Ltd.−$5.3m−150.9K
IMVTImmunovant, Inc.−$873,128−22.7K

Change in shares on the previous quarter's 13F, valued at this quarter's reported price.

CompanyValue last quarterShares
ABVXAbivax S.a.$97.5m875.8K
SYRESpyre Therapeutics, Inc.$50.4m1.00M
IMCRImmunocore Holdings plc$22.1m734.4K
CTNMContineum Therapeutics, Inc.$18.6m1.42M
ARGXArgenx SE$18.4m25.2K
CMPSCompass Pathways plc$13.0m2.34M
PHVSPharvaris N.V.$10.6m375.0K
  • Health Care100.0%

Share of the value held in companies we cover, by sector.

PeriodCopy, a yearS&P 500SharpeS&P 500Biggest dropBeta
Whole backtestAugust 16, 2013 to November 2, 2026+11.0%+14.1%0.420.78−60.3%0.97
2018 onwardsJanuary 5, 2018 to November 2, 2026+5.5%+13.9%0.240.66−60.3%0.90
Last three yearsNovember 3, 2023 to November 2, 2026+31.8%+21.8%0.941.16−22.5%0.98
Last yearNovember 7, 2025 to November 2, 2026+26.4%+14.2%0.850.84−13.6%0.93

From SEC Form 13F data sets. A 13F lists long positions in US-listed shares at the quarter's end, filed up to 45 days later; it does not show shorts, cash, bonds, non-US holdings or trades within the quarter. Positions in companies outside our coverage are not listed here. Research, not investment advice.